There is an artificial intelligence boom happening in the life sciences sector, says Guido Lanza, president and CEO of AI biotech company Numerate Inc., but pharma and biotech are playing catch-up to other industries where this technological advancement is already being successfully applied.
What's Next For Artificial Intelligence In The Clinic?
Numerate CEO Guido Lanza talks to Scrip about how artificial Intelligence, or AI, has been quietly used by some drug developers for the last decade, but its use is now rocketing. Also, what is next for AI in pharma?
More from AI
• By
In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?